drugset / Trial / NCT03685500
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase IV, multicentre, randomised, open-label, pilot clinical trial to evaluate the Reversibility of abacavir/lamivudine/dolutegravir ( ABC/3TC/DTG) CNS-Related Neurotoxicity After Switching to tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c)
Timeline
- Start
- 2018-12-04
- Primary completion
- 2020-06-25
- Completion
- 2020-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ABC | Unknown | — | — |
| Comparator | DTG | Unknown | — | — |
| Comparator | Lamivudine | Other / unclassified | — | — |
| Subject | Symtuza | Unknown | — | — |